Total plasma concentration in CD1 mouse assessed as (2R,3R,4R,5R,6R)-5-acetamido-4-amino-2,3-difluoro-6-((1R,2R)-1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid at 30 mg/kg, po measured at 20 mins by reversed-phase UPLC/MS analysis
Total plasma concentration in CD1 mouse assessed as (2R,3R,4R,5R,6R)-5-acetamido-4-amino-2,3-difluoro-6-((1R,2R)-1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid at 30 mg/kg, po measured at 60 mins by reversed-phase UPLC/MS analysis
Tmax in CD1 mouse assessed as (2R,3R,4R,5R,6R)-5-acetamido-4-amino-2,3-difluoro-6-((1R,2R)-1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid at 30 mg/kg, po
Cmax in CD1 mouse assessed as (2R,3R,4R,5R,6R)-5-acetamido-4-amino-2,3-difluoro-6-((1R,2R)-1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid at 30 mg/kg, po
AUC in CD1 mouse assessed as (2R,3R,4R,5R,6R)-5-acetamido-4-amino-2,3-difluoro-6-((1R,2R)-1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid at 30 mg/kg, po
Oral bioavailability in CD1 mouse assessed as (2R,3R,4R,5R,6R)-5-acetamido-4-amino-2,3-difluoro-6-((1R,2R)-1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid at 30 mg/kg